k8凯发(中国)天生赢家·一触即发

News Center
Share the latest news with you
IMPACT Therapeutics to present Ph3 pivotal clinical trial data of Senaparib (IMP4297) as Maintenance Treatment in Patients with Advanced Ovarian Cancer at the 2023 ESMO Congress as Late-Breaking Abstract
2023-09-29

Shanghai, China, September 29, 2023--IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced that at the European Society of Medical Oncology (ESMO) Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, an oral presentation will showcase the efficacy and safety of Senaparib (IMP4297) as maintenance treatment in patients with newly diagnosed advanced Ovarian cancer (FLMAES Study) as Late-breaking Abstract.

 

 

Presentation details as below:
 
Presentation Title: Efficacy and Safety of Senaparib as Maintenance Treatment in Patients with Newly Diagnosed Advanced Ovarian Cancer (FLAMES Study): A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
 
Presentation Number: #LBA36
 
Type: Late-breaking Oral
 
Speakers: Xiaohua Wu (Shanghai, China)
 
Session: Proffered Paper session – Gynaecological cancers
 
Presentation Date/Time: Fri, 10/20/23 16:00-16:10
 
Room: Sevilla Auditorium-Hall 9
 
 
About the FLAMES Study
The FLAMES Study is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evalsuate the efficacy and safety of Senaparib as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III/IV ovarian cancer who have achieved complete response (CR) or partial response (PR). The study results demonstrate that Senaparib maintenance therapy significantly prolongs progression-free survival (PFS) of advanced ovarian cancer patients, regardless of BRCAm status. Additionally, Senaparib exhibits a well-tolerated and manageable safety profile.
 
 
About Senaparib
Senaparib is a novel potent and selective PARP inhibitor, which has completed phase 1 clinical study in Australia and China, and has met its primary endpoint for advanced ovarian cancer maintenance treatment following first-line therapy in the pivotal FLAMES phase 3 study. In September 2023, Impact Therapeutics announced that the National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Senaparib in China, as a first-line maintenance treatment of adult patients with ovarian epithelial carcinoma, fallopian tube cancer or primary peritoneal cancer following a response to platinum-based chemotherapy. In addition, in August 2022, the fixed dose combination capsules of Senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA).
 

About IMPACT Therapeutics
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT has assembled one of the most comprehensive DNA damage response (DDR) global pipelines of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/IMP4297), which has successfully completed Phase III pivotal trial in ovarian cancer first-line maintenance setting with best-in-class efficacy and safety profile. Senaparib is currently under NMPA NDA review in China. In addition, Impact is also developing WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064), and PARP1 selective inhibitor (IMP1734, in collaboration with Eikon Therapeutics), as well as other novel DDR pathway inhibitors.
 
 
IMPACT Therapeutics Contact Information:
 
Email: info@getunderline.com
 
 
 
 
 
 
 
 
News Recommendation
网站首页
k8凯发天生赢家·一触即发